ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-10-02

Study Completion Date

2019-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase I/II protocol to evaluate the safety and efficacy of ADA gene transfer into hematopoietic stem/progenitor cells for the treatment of adenosine deaminase (ADA)-deficiency. This condition is an autosomal recessive form of Severe Combined Immunodeficiency (SCID) characterized by impaired immune responses, recurrent infections, failure to thrive and systemic toxicity due to accumulation of purine metabolites. Transplants from an human leukocyte-antigen (HLA)-identical sibling donor is the treatment of choice, but available for a minority of patients. The use of alternative bone marrow donors or enzyme replacement therapy is associated with important drawbacks. The drug product studied in this protocol consists of autologous cluster of differentiation (CD)34+ hematopoietic stem/progenitor cells engineered ex vivo with a retroviral vector encoding the therapeutic gene ADA. The engineered CD34+ cells are infused following a nonmyeloablative conditioning with busulfan to make space in the bone marrow. The study objectives are: a) to evaluate the safety and the clinical efficacy of gene therapy, in the absence of enzyme replacement therapy; b) to evaluate the biological activity (engraftment, ADA expression) of ADA transduced CD34+ cells and their hematopoietic progeny. c) to evaluate the immunological reconstitution and purine metabolism after gene therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency

NCT00018018

Severe Combined Immunodeficiency Syndrome

COMPLETED PHASE1

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

NCT01852071

ADA-SCID

COMPLETED PHASE1/PHASE2

MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID

NCT00794508

Severe Combined Immunodeficiency

COMPLETED PHASE2

Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

NCT05432310

Adenosine Deaminase Severe Combined Immune Deficiency

RECRUITING PHASE1/PHASE2

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

NCT00516152

Chronic Myeloid Leukemia Acute Myelogenous Leukemia Myelodysplasia +6 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The safety of the study will be evaluated by description of all adverse events and adverse drug reactions.

The study is aimed at reaching the minimum sample size of ten patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunologic Deficiency Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gene Therapy

Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan

Group Type EXPERIMENTAL

Gene Therapy

Intervention Type GENETIC

Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan

Busulfan

Intervention Type DRUG

Busulfan is used for non-myeloablative conditioning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gene Therapy

Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan

Intervention Type GENETIC

Busulfan

Busulfan is used for non-myeloablative conditioning

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gene transduced CD34+ cells GSK2696273 Strimvelis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ADA-SCID with no HLA-identical sibling donor available
* pediatric age and at least one of the following criteria:
* inadequate immune response after PEG-ADA for \> 6 months
* patients who discontinued PEG-ADA due to intolerance, allergy or auto-immunity
* patients for whom enzyme replacement therapy is not a life long therapeutic option

Exclusion Criteria

* HIV infection
* history or current malignancy
* Patients who received a previous gene therapy treatment in the 12 months prior to receiving Strimvelis
* any other conditions dangerous for the patients according to the investigator

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No